Literature DB >> 22492255

Tobacco use and cancer survival: a cohort study of 40,230 Swedish male construction workers with incident cancer.

Caroline Nordenvall1, Per J Nilsson, Weimin Ye, Therese M-L Andersson, Olof Nyrén.   

Abstract

On theoretical grounds, nicotine has been implicated as a modifier of cancer progression. We investigated possible associations of smoking or use of Scandinavian moist snuff (snus) with survival after cancer among Swedish male construction workers. Snus use is associated with substantial exposure to nicotine but not to the combustion products in smoke. Among 336,381 workers with detailed information on tobacco use in 1971-1992, we observed 40,230 incident cancers. Complete follow-up through 2007 was accomplished through linkage to population and health registers. Hazard ratios (HRs) and 95% confidence intervals (CIs) for death from any cause, cancer-specific death and death from other causes were derived from Cox proportional hazards regression models adjusted for age at diagnosis, body mass index at study entry and period of diagnosis. Never users of any tobacco served as reference. Increased risks of cancer-specific death were observed both among exclusive smokers (HR(all cancer) 1.15, 95% CI: 1.10-1.21) and never-smoking snus users (1.15, 95% CI: 1.05-1.26). As regards deaths due to other causes, exclusive smokers had higher relative risks than exclusive snus users (p = 0.03). A history of tobacco use, even exclusive use of the seemingly benign snus, is associated with moderately increased cancer-specific mortality. Although nicotine might play a role, the mechanisms warrant further investigation.
Copyright © 2012 UICC.

Entities:  

Mesh:

Year:  2012        PMID: 22492255     DOI: 10.1002/ijc.27587

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Adult interest in using a hypothetical modified risk tobacco product: findings from wave 1 of the Population Assessment of Tobacco and Health Study (2013-14).

Authors:  Jennifer L Pearson; Amanda L Johnson; Sarah E Johnson; Cassandra A Stanton; Andrea C Villanti; Raymond S Niaura; Allison M Glasser; Baoguang Wang; David B Abrams; K Michael Cummings; Andrew Hyland
Journal:  Addiction       Date:  2017-09-06       Impact factor: 6.526

2.  Snus use, smoking and survival among prostate cancer patients.

Authors:  Kathryn M Wilson; Sarah C Markt; Fang Fang; Caroline Nordenvall; Jennifer R Rider; Weimin Ye; Hans-Olov Adami; Pär Stattin; Olof Nyrén; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2016-12-15       Impact factor: 7.396

3.  A Systematic Analysis of Candidate Genes Associated with Nicotine Addiction.

Authors:  Meng Liu; Xia Li; Rui Fan; Xinhua Liu; Ju Wang
Journal:  Biomed Res Int       Date:  2015-05-04       Impact factor: 3.411

Review 4.  Epidemiological evidence relating snus to health--an updated review based on recent publications.

Authors:  Peter N Lee
Journal:  Harm Reduct J       Date:  2013-12-06

5.  Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies.

Authors:  Marja Lisa Byhamre; Marzieh Araghi; Lars Alfredsson; Rino Bellocco; Gunnar Engström; Marie Eriksson; Maria Rosaria Galanti; Jan-Håkan Jansson; Anton Lager; Michael Lundberg; Per-Olof Östergren; Nancy L Pedersen; Ylva Trolle Lagerros; Weimin Ye; Patrik Wennberg; Cecilia Magnusson
Journal:  Int J Epidemiol       Date:  2021-01-23       Impact factor: 7.196

6.  Tobacco endgames: what they are and are not, issues for tobacco control strategic planning and a possible US scenario.

Authors:  Ruth E Malone
Journal:  Tob Control       Date:  2013-05       Impact factor: 7.552

Review 7.  Nicotine: Carcinogenicity and Effects on Response to Cancer Treatment - A Review.

Authors:  Tore Sanner; Tom K Grimsrud
Journal:  Front Oncol       Date:  2015-08-31       Impact factor: 6.244

8.  Lifestyle factors associated with survival after colorectal cancer diagnosis.

Authors:  T Boyle; L Fritschi; C Platell; J Heyworth
Journal:  Br J Cancer       Date:  2013-06-20       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.